View:
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
__________________
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
__________________
Date of
Report (Date of earliest event reported):
May
9, 2008
BIOSANTE
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-31812
|
58-2301143
|
|
(State
or Other Jurisdiction of Incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification Number)
|
|
111
Barclay Boulevard
Lincolnshire,
Illinois
|
60069
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(847)
478-0500
(Registrant’s
Telephone Number, Including Area Code)
N/A
(Former
Name or Former Address, If Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
£
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
£
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
£
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
£
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Section
2 – Financial Information
Item 2.02. Results of Operations and
Financial Condition.
On May 9,
2008, BioSante Pharmaceuticals, Inc. publicly announced its financial results
for the first quarter ended March 31, 2008. For further information,
please refer to the press release attached hereto as Exhibit 99.1, which is
incorporated by reference herein.
The
information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be
deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability
of that section, and shall not be incorporated by reference into any filings
made by BioSante Pharmaceuticals, Inc. under the Securities Act of 1933, as
amended, or the Exchange Act, except as may be expressly set forth by specific
reference in such filing.
Section
9 – Financial Statements and Exhibits
Item
9.01. Financial Statements and Exhibits.
(c) Exhibits.
|
Exhibit
No.
|
Description
|
|
99.1
|
Press
Release issued May 9, 2008
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
BIOSANTE
PHARMACEUTICALS, INC.
By: /s/ Phillip B.
Donenberg
Phillip
B. Donenberg
Chief
Financial Officer, Treasurer and Secretary
Dated: May 9, 2008
BIOSANTE
PHARMACEUTICALS, INC.
FORM
8-K
Exhibit
Index
|
Exhibit
No.
|
Description
|
Method
of Filing
|
|
99.1
|
Press
Release issued May 9, 2008
|
Furnished
herewith
|
BioSante
Pharmaceuticals, Inc.
111
Barclay Boulevard
Lincolnshire,
Illinois 60069
www.biosantepharma.com
FOR
IMMEDIATE
RELEASE
NASDAQ:
BPAX
BioSante
Pharmaceuticals Reports
First
Quarter 2008 Financial Results
LINCOLNSHIRE, Illinois - (May 9, 2008) --- BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today
reported its March 31, 2008 financial results and cash balance for the first
quarter ended March 31, 2008.
BioSante
incurred a net loss of approximately $3.6 million or ($0.13) per share for the
quarter ended March 31, 2008, compared to a net loss of $1.8 million or ($0.08)
per share for the same period in 2007. This planned increase was due
primarily to the conduct of the three ongoing LibiGel®
(testosterone gel) Phase III clinical studies to support submission of a new
drug application (NDA) and U.S. Food and Drug Administration (FDA)
approval. The LibiGel Phase III safety and efficacy studies are being
conducted under an FDA approved SPA (special protocol assessment).
The
Company’s cash, cash equivalents and short-term investments as of March 31, 2008
were approximately $27.6 million, as compared to approximately $30.7 million on
December 31, 2007.
About
BioSante Pharmaceuticals, Inc.
BioSante
is a specialty pharmaceutical company focused on developing products for female
sexual health, menopause, contraception and male hypogonadism. BioSante's lead
products include LibiGel®
(transdermal testosterone gel) in Phase III clinical development by BioSante
under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol
Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™
(estradiol gel) developed through FDA approval by BioSante, indicated for the
treatment of moderate-to-severe vasomotor symptoms associated with menopause,
currently marketed in the U.S. Also in development are Bio-T-Gel™, a
testosterone gel for male hypogonadism, and an oral contraceptive in Phase II
clinical development using BioSante patented technology. The
current market in the U.S. for estrogen and testosterone products is
approximately $2.5 billion and for oral contraceptives approximately $3.0
billion. The company also is developing its calcium phosphate technology (CaP)
for novel vaccines, drug delivery and aesthetic medicine
(BioLook™). Additional information is available online at: www.biosantepharma.com.
For more
information, please contact:
Alan Zachary,
McKinney/Chicago; (312) 944-6784 ext. 316; azachary@mckinneychicago.com;
www.mckinneychicago.com